Alimera Sciences Inc (ALIM) 2.04 $ALIM Alimera Sciences

New Post Public Reply Private Reply Replies (0) Message Board

Aug 1, 2016 at 2:24 PM

Alimera Sciences Inc (ALIM) 2.04 $ALIM

Alimera Sciences (ALIM) Shares March Higher, Can It Continue?
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 8:57AM CDT
As of late, it has definitely been a great time to be an investor in Alimera Sciences Inc (ALIM)
ALIM: 2.04 (-0.01)

Five Trending Stocks Leading Biotech Sector on Heels of Latest R&D and Innovative Drug Therapy Advancements
PR Newswire Europe - Wed Jul 27, 7:31AM CDT
CORAL SPRINGS, Florida, July 27, 2016 /PRNewswire/ --
KOOL: 4.50 (+0.32), ALIM: 2.04 (-0.01), CBIO: 1.45 (-0.04), EXAS: 17.91 (+0.53)

Alimera Sciences Pre-Announces Record Second Quarter 2016 Revenue
GlobeNewswire - Tue Jul 26, 6:31AM CDT
-- Second Quarter 2016 Revenue to be in the range of $9.3 million to $9.5 million, an increase of over 50% versus First Quarter 2016
HTGC: 13.24 (-0.02), ALIM: 2.04 (-0.01)

Alimera Sciences to Present at the Cantor Fitzgerald Conference
GlobeNewswire - Wed Jul 06, 1:01PM CDT
Alimera Sciences (NASDAQ:ALIM), a leader in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Chief Executive Officer, Dan Myers, will present at the Cantor Fitzgerald Conference, to be held July 12 - 13, 2016 at Le Parker Meridien Hotel in New York, NY. The Company's presentation will take place Tuesday, July 12, 2016, at 2:30 PM Eastern Time.
ALIM: 2.04 (-0.01)

Alimera Sciences to Present at the LD Micro Invitational Conference
GlobeNewswire - Thu Jun 02, 6:00AM CDT
Alimera Sciences (NASDAQ:ALIM), a leader in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Chief Executive Officer, Dan Myers, will present at the LD Micro Invitational Conference, to be held June 7 - 9, 2016 at the Luxe Sunset Boulevard Hotel in Los Angeles, California. The Company's presentation will take place Wednesday, June 8, 2016 at 8:30 AM Pacific Time.
ALIM: 2.04 (-0.01)

Real World Data In Europe Show Majority Of Diabetic Macular Edema Patients Gain Or Maintain Vision With Iluvien(R) At 12 Months
GlobeNewswire - Mon May 23, 3:00PM CDT
Despite other prior treatments, improvements in visual acuity and retinal thickness were seen in the majority of patients
ALIM: 2.04 (-0.01)

Alimera Sciences to Present at the UBS Global Healthcare Conference
GlobeNewswire - Tue May 17, 6:30AM CDT
Alimera Sciences (NASDAQ:ALIM), a leader in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Chief Executive Officer, Dan Myers, will present at the UBS Global Healthcare Conference, to be held May 23 - 25, 2016 at the The Grand Hyatt in New York City, New York. The Company's presentation will take place Monday, May 23, 2016 at 11:30 AM Eastern Time.
ALIM: 2.04 (-0.01)

Alimera Sciences' ILUVIEN(R) Data Presented at SFO 2016
GlobeNewswire - Wed May 11, 6:30AM CDT
Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that data from six ILUVIEN post marketing studies were presented during the French Society of Ophthalmology 122nd Congress (SFO 2016) in Paris May 7-10.
ALIM: 2.04 (-0.01)

Alimera Sciences' ILUVIEN® Data Presented At 2016 ARVO
PR Newswire - Fri May 06, 6:30AM CDT
Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that data from seven ILUVIEN® post marketing studies were presented during the 2016 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Seattle, May 1-5.
ALIM: 2.04 (-0.01)

Alimera Sciences reports 1Q loss
Automated Insights - Wed May 04, 6:48PM CDT
ALPHARETTA, Ga. (AP) _ Alimera Sciences Inc. (ALIM) on Wednesday reported a loss of $11.1 million in its first quarter.
ALIM: 2.04 (-0.01)

Alimera Sciences Announces First Quarter 2016 Financial Results
GlobeNewswire - Wed May 04, 3:23PM CDT
-- First quarter revenue improved 49% compared to first quarter 2015 due to increasing ILUVIEN(R) sales in the U.S.
ALIM: 2.04 (-0.01)

Stonegate Capital Partners Initiates Coverage on Alimera Sciences
ACCESSWIRE - Wed Apr 27, 8:02AM CDT
DALLAS, TX / ACCESSWIRE / April 27, 2016 / Stonegate Capital Partners initiates research coverage on Alimera Sciences, Inc. (NASDAQ: ALIM).
ALIM: 2.04 (-0.01), REGN: 434.41 (+9.29)

Alimera Sciences to Report First Quarter 2016 Financial Results on May 4, 2016
GlobeNewswire - Tue Apr 26, 8:58AM CDT
Alimera Sciences (NASDAQ:ALIM), a leader in research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release its financial results for the period ended March 31st, 2016, at the close of the financial markets on May 4, 2016.
ALIM: 2.04 (-0.01)

New Strong Sell Stocks for April 21st
Zacks Equity Research - Zacks Investment Research - Thu Apr 21, 6:46AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Thursday
AAOI: 12.16 (+0.32), ALIM: 2.04 (-0.01), ARES: 17.23 (-0.12), AXTA: 28.57 (+0.02), ARNA: 1.68 (+0.01)

New Strong Sell Stocks for April 18th
Zacks Equity Research - Zacks Investment Research - Mon Apr 18, 6:42AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Monday
CRME: 3.19 (+0.06), ALIM: 2.04 (-0.01), CAR: 36.46 (-0.27), BAC: 14.40 (-0.09), CWT: 34.01 (+0.28)

New Strong Sell Stocks for March 31st
Zacks Equity Research - Zacks Investment Research - Thu Mar 31, 7:37AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Thursday
AXE: 60.11 (-1.17), ALIM: 2.04 (-0.01), AMD: 6.69 (-0.17), CWT: 34.01 (+0.28), ATRS: 1.02 (+0.02)

New Strong Sell Stocks for March 16th
Zacks Equity Research - Zacks Investment Research - Wed Mar 16, 7:29AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Wednesday
FITB: 18.89 (-0.09), CECE: 9.10 (-0.15), ALIM: 2.04 (-0.01), FBC: 26.44 (+0.03), FCFS: 51.35 (+0.04)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Venice's Climate Challenge: Rising Seas, Sinking Lands

Sea Rise Isn’t Just a Statistics Problem The ordeal of rising seas isn't just about staring at numbers in some spreadsheet, it's a real-world gut punch that's knocking at Venice's door. This city, known for its stunning architecture and winding canals, now serves as the poster child for what happens when Mother Nature and human errors leave a place on the brink of...

Aetna's 2027 Medicare Plans: Comprehensive Outlook

Unpacking Aetna's Medicare Strategy for 2027 Look, if there's one thing you should keep tabs on, it's how Aetna isn't just coasting by in the healthcare arena. These folks are pushing forward with new options for 2027 that prove they're serious about making healthcare not just accessible, but affordable across the board. Aetna, backed by CVS Health (NYSE: CVS), is making...

Trading Platforms Poised for Billions by 2031

Forecasts and Fierce Digital Landscapes Just when you thought the online trading realm was getting saturated, the numbers are making it clear: there’s still room for growth—even explosive growth. The online trading platform market is eyeing a hike, jumping from a $11.65 billion valuation in 2025 to a projected $18.18 billion by 2031, according to Mordor Intelligence....

Vatrer Power: Lithium Batteries Revolutionize Golf Carts

The humdrum world of golf carts just got a jolt of energy with lithium batteries entering the fray. Vatrer Power, the brain behind some nifty LiFePO4 lithium battery conversions, made some noise at this year's Golf Carting Expo & Dealer Summit in Charleston, South Carolina. Held at the North Charleston Convention Center, this trade show was the industry's premier...

Govee Stirs Halloween Chills with New Sarah Gellar Ad

Lighting Up Halloween the Hollywood Way When it comes to Halloween, folks go nuts driving up the thrill factor at home, and boy, has Govee nailed it this time around. They've dragged Sarah Michelle Gellar into their spooky mix, transforming homes into eerie masterpieces. And let's face it, who better than the 'Buffy the Vampire Slayer' herself to stir those spine-tingling...

Ractigen's Breakthrough in DMD: RNA Activates Utrophin

Ractigen's New Fight Against Duchenne: A Personal Take When it comes to biotech advancements, I've seen enough breakthroughs to not get swayed easily. But Ractigen Therapeutics presenting their first-in-human data on RNA activation for Duchenne Muscular Dystrophy (DMD) kind of demands your attention. Folks, they're talking about a potential shift in handling this brutal...

The Real Cost of Cabinet Decisions: Refinish or Replace?

Uncovering the Truth Behind Cabinet Decisions When it comes to sprucing up a kitchen, most folks overlook what's hanging on their walls already: those tired old cabinets. Now, are you looking at chucking them out the window for brand-new ones, or can a fresh coat of paint breathe new life into them? Well, that's where Melvin Jones, a painting virtuoso from Lexington,...

Kal Plastics Showcases at Design-2-Part Expo

Kal Plastics Steps into the Limelight There's a buzz in the air, and it's all about Kal Plastics getting ready to strut their stuff at the Southern California Design-2-Part Show. Now, most folks probably don't spend their nights dreaming about thermoforming and pressure forming, but these guys sure make a case for it. They’ve got their eyes on impressing the crowd with...

Honeywell's Supply Line Snags Bait Class Action Risk

Stepping into the chaos of the stock market sometimes feels like opening Pandora's box—just when you think you've seen it all, something new tumbles out. This time around, it's Honeywell Aerospace (NasdaqGS: HONA) playing catch with hot coals, and a burning class-action lawsuit smolders in the air. Deadline Looms for Investors in Class Action Heads up, folks! If you've...